ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Novavax and Moderna side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

NovavaxModerna
studies on the registry48119
open to participants now018
phase 3 studies under way02
reach primary completion within a year016
programswith a study of their own in two years116

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseNovavaxModerna
Phase 100%

Moderna: 5 of its 16 programs at phase 1

  1. MRNA-1365phase 1
  2. MRNA-1469phase 1
  3. mRNA-1519phase 1
  4. MRNA-4106phase 1
  5. MRNA-4200phase 1
31%
Phase 200%31%
Phase 300%

Moderna: 3 of its 16 programs at phase 3

  1. mRNA-1345 respiratory syncytial virus vaccinephase 3
  2. MRNA-1018phase 3
  3. MRNA-1083phase 3
19%
Approved, new studies

Novavax: 1 of its 1 programs at approved, new studies

  1. NVX-COV2705approved, new study
100%

Moderna: 3 of its 16 programs at approved, new studies

  1. 2019-nCoV Vaccine mRNA-1273approved, new study
  2. MRNA-1283approved, new study
  3. mRNA-1010 influenza vaccineapproved, new study
19%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Novavax0 readouts · 0 phase 3············
Moderna9 readouts · 4 phase 3·

Moderna, Dec ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. mRNA-1010 influenza vaccineapproved, new study · Dec 7 · NCT07884175
  2. 2019-nCoV Vaccine mRNA-1273approved, new study · Dec 11 · NCT07863635
  3. MRNA-1283approved, new study · Dec 11 · NCT07863635

Moderna, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. MRNA-1018phase 3 · Jan 28 · NCT07496450
···

Moderna, May ’27: 1 program whose next study reaches primary completion

  1. Lipid Nanoparticle-encapsulated EBV mRNA Vaccine mRNA-1189phase 2 · May 15 · NCT07478952
·

Moderna, Jul ’27: 1 program whose next study reaches primary completion

  1. MRNA-1365phase 1 · Jul 20 · NCT07764237

Moderna, Aug ’27: 2 programs whose next study reaches primary completion

  1. MRNA-4106phase 1 · Aug 3 · NCT06880549
  2. MRNA-4200phase 1 · Aug 3 · NCT06880549

Moderna, Sep ’27: 1 program whose next study reaches primary completion

  1. MRNA-1469phase 1 · Sep 30 · NCT07737717
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Novavax

New programs 0

None

Reached a new phase 0

None

Study stopped 1

  • NVX-COV2705approved, new study · terminated Oct 23 · none of its studies left running“The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaning…” · NCT07086222

Primary completion later 0

None

Moderna

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionNovavaxModerna
COVID-19both · compare here

Novavax in COVID-19: 1 program

  1. NVX-COV2705approved, new study

Their studies: Novavax’s studies of COVID-19 in search

Moderna in COVID-19: 3 programs

  1. MRNA-1083phase 3
  2. 2019-nCoV Vaccine mRNA-1273approved, new study
  3. MRNA-1283approved, new study

Their studies: Moderna’s studies of COVID-19 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Novavax 0 of 1 · Moderna 5 of 16 programs. Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.